NCT01375465Unknown4 期
The 001-DIOR Multicenter Registry (A Novel Percutaneous Coronary Intervention With the New Paclitaxel-eluting Balloon DIOR in Ostial Bifurcated Lesions)
适应症
干预措施
试验速览
- 阶段
- 4 期
- 发起方
- Eurocor GmbH
- 入组人数
- 50
- 试验地点
- 3
- 主要终点
- Major adverse cardiac events (MACE)
研究概览
简要总结
The 001 DIOR study is a prospective, multicenter registry of percutaneous coronary intervention (PCI) to assess the clinical success, efficacy and safety of the Paclitaxel-eluting balloon DIOR (Eurocor GmbH, Germany) for the treatment of de novo ostial bifurcated lesions (001 of Medina classification). The DIOR balloon will be used to treat the stenotic site branch.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •De novo bifurcated lesions 001 of Medina classification, with significant stenosis only in the ostium of the side branch and a reference vessel diameter is bigger or equal 2.0mm; the DIOR balloon will be used to the treat the side branch.
- •The patient has clinical evidence of myocardial ischemia (stable or unstable angina, acute and non acute myocardial infarction, silent ischemia: ECG, exercise test, etz...)
- •As the maximal length of the DIORTM balloon is 30 mm, all eligible lesions should be no longer than 25 mm to ensure an adequate drug elution in the treated segment, avoiding the phenomenon of "geographical miss" .
- •Target lesion(s) stenosis is more or equal 50% by visual estimation.
排除标准
- •Cardiogenic shock
- •Any serious disease that might limit patient survival to less than one year
- •Inability to perform clinical follow-up for a period of 1 year
- •Left main bifurcation lesions: ostial left circumflex or ostial left anterior descending artery stenosis.
- •Lesion length > 25 mm
- •Target vessel reference diameter < 2mm
- •Stenosis < 50% of the reference luminal diameter
- •Severe angiographic calcification at the level of the target lesion
研究组 & 干预措施
Dior
Other
One arm observational registry using the Dior paclitaxel eluting balloon for the treatment of de novo ostial bifurcated lesions.
干预措施: DIOR drug-eluting PTCA balloon (Device)
结局指标
主要结局
Major adverse cardiac events (MACE)
时间窗: 6 months
MACE rate defined as the rate of cardiac death and/or myocardial infarction (MI) and/or target lesion revascularization (TLR)
次要结局
- target vessel revascularization (TVR) rate, either symptom or ischemia-driven(6 months)
- Segment treated thrombosis (STT), according to ARC definitions(6 months)
- Late Lumen Loss(6 months)
- Binary restenosis rate(6 months)
研究者
研究点 (3)
Loading locations...
相似试验
进行中（未招募）
不适用
PARK RegistryCTRI/2017/10/010137Cardiological Society of India Kerala Chapter
招募中
不适用
The Percutaneous Coronary Intervention Registry in University Medical Center of Ho Chi Minh CityCoronary Artery DiseaseNCT06071741University Medical Center Ho Chi Minh City (UMC)3,600
招募中
不适用
Percutaneous Coronary Intervention Registry FRIBOURGPercutaneous Coronary InterventionCoronary Artery DiseaseNCT04185285University of Freiburg3,000
Unknown
不适用
Beijing Percutaneous Coronary Intervention RegistryCoronary Heart DiseaseNCT01417325Chinese Academy of Medical Sciences, Fuwai Hospital700,000
Unknown
不适用
Percutaneous Coronary Intervention in Patients witH OrthotoPic hEart Transplantation: the PCI-HOPE a Multicenter Study.Heart Transplant Failure and RejectionCoronary Artery DiseaseNCT03538509Fabrizio D'Ascenzo150